Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma

Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma

Pulmonary toxicity during Hodgkin lymphoma treatment is significant for a variety of reasons, ranging from clinical care to therapeutic innovation and patient outcomes.

Understanding chemotherapy-induced pulmonary issues, particularly bleomycin-induced toxicity, might enhance treatment efficacy, side effects, and quality of life for Hodgkin lymphoma patients. For Hodgkin lymphoma chemotherapy patients with pulmonary difficulties, which result in significant patient morbidity and mortality, early detection, proactive surveillance, and rapid management are required. Identifying the prevalence, risk factors, and clinical signs of pulmonary toxicity helps clinicians stratify treatment.

Inclusion Criteria:

• Patients diagnosed with Hodgkin lymphoma (HL) receiving treatment.
• Patients of all ages and both genders.
• Patients with histologically confirmed HL, as per the WHO 2016 classification.
• Patients who have undergone pulmonary function testing and assessment at specified time points during their treatment course.
• Patients with complete medical records documenting treatment regimens, including chemotherapy and radiotherapy details.

Exclusion Criteria:

• Patients with a diagnosis of another malignancy.
• Patients with incomplete medical records or missing data on treatment regimens and pulmonary function assessments.
• Patients with a history of significant pulmonary comorbidities, such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, or pulmonary fibrosis, before HL diagnosis.
• Patients who are unable to complete pulmonary function tests.